These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19801161)

  • 1. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
    Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
    Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9.
    Okuducu AF; Zils U; Michaelis SA; Mawrin C; von Deimling A
    Cancer; 2006 Sep; 107(6):1365-72. PubMed ID: 16894529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A5: a marker of recurrence in WHO grade I meningiomas.
    Hancq S; Salmon I; Brotchi J; De Witte O; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):178-87. PubMed ID: 15043715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
    Korshunov AG; Shishkina LV; Golanov AV
    Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin predicts the behaviour of atypical meningioma.
    Lin CK; Tsai WC; Lin YC; Hueng DY
    Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of p63 immunoreactivity with tumor grade in meningiomas.
    Rushing EJ; Olsen C; Man YG
    Int J Surg Pathol; 2008 Jan; 16(1):38-42. PubMed ID: 18203782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.
    Pistolesi S; Boldrini L; Gisfredi S; De Ieso K; Camacci T; Caniglia M; Lupi G; Leocata P; Basolo F; Pingitore R; Parenti G; Fontanini G
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):118-25. PubMed ID: 15043709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of cathepsin D in meningiomas.
    Castilla EA; Prayson RA; Abramovich CM; Cohen ML
    Am J Clin Pathol; 2003 Jan; 119(1):123-8. PubMed ID: 12520707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas].
    Hernández Faraco A; Céspedes G; Trejo E
    Neurologia; 2009 May; 24(4):235-44. PubMed ID: 19603293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma.
    Shayanfar N; Mashayekh M; Mohammadpour M
    Acta Med Iran; 2010; 48(3):142-7. PubMed ID: 21137648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on the recurrence of meningiomas: correlating factors for the recurrence and therapeutic prognosis of meningiomas].
    Miyagami M; Miyagi A; Kido G; Tsubokawa T
    No Shinkei Geka; 1994 May; 22(5):421-8. PubMed ID: 8196827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caveolin-1 in meningiomas: expression and clinico-pathological correlations.
    Barresi V; Cerasoli S; Paioli G; Vitarelli E; Giuffrè G; Guiducci G; Tuccari G; Barresi G
    Acta Neuropathol; 2006 Nov; 112(5):617-26. PubMed ID: 16850311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.